Company

Palleon Pharmaceuticals Inc.

Palleon Pharmaceuticals develops glycan editing therapies aimed at treating cancer and autoimmune diseases.

About

Palleon Pharmaceuticals is a Waltham, US company founded in 2016 that develops glycan editing therapies, using glycobiology techniques, for cancer and autoimmune diseases. CEO Jim Broderick leads the company, which completed a Series B round in September 2020 raising USD 100.000 mn, bringing the total raised to USD 100.000 mn at a post-money valuation of USD 238.830 mn. The round was led by Matrix Capital Management, with participation from AbbVie Biotech Ventures and Pfizer Venture Investments.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in